The invention provides a crystalline form of (2S, 4R)-5-biphenyl-4-yl-2- hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.本發明提供(2S,4R)-5-聯苯-4-基-2-羥甲基-2-甲基-4-[(1H-[1,2,3]三唑-4-羰基)胺基]戊酸5-甲基-2-酮基-[1,3]二氧雜環戊烯-4-基甲酯或其互變異構體之結晶型。本發明亦提供包含該結晶化合物之醫藥組合物、用於製備該結晶化合物之方法及中間物以及使用該結晶化合物治療疾病之方法。
